Lancashire and South Cumbria
Formulary
Formulary
5 Infections
Prescribers must follow the relevant local and national guidance when treating an infection. Some anti-infectives require approval from the local Trust microbiology team for use, consult local guidance for further information.Not all anti-infectives listed in this chapter will be available in all localities; availability will be guided by local need and resistance patterns. |
05-02 Antifungal drugs
| Amphotericin B (liposomal) |
|
Formulary
|
Powder for dispersion for infusion 50mg |
 MHRA: Liposomal and lipid-complex formulations: name change to reduce medication errors MHRA: Parenteral amphotericin B: reminder of risk of potentially fatal adverse reaction if formulations confused |
|
| Flucytosine Ancotil® |
|
Formulary
|
Intravenous infusion 2.5g/250mL On advice of Microbiology only. |
|
MHRA: Flucytosine (Ancotil): new contraindication in patients with DPD deficiency |
|
|
All other indications, on advice of Microbiology only.| Micafungin |
|
Formulary
|
Intravenous infusion 50mg, 100mg Paediatric use only. On advice of Microbiology only. |
|
|
| Nystatin |
|
Formulary
|
 Oral suspension 100 000units/mL Pessary 100 000 units (unlicensed product)For recurrent vulvovaginal candidiasis with non-albicans candida species and azole resistance. On advice of microbiology, gynaecology or dermatology only. |
|
BASHH: Vulvovaginal Candidiasis 2019 |
|
| Posaconazole |
|
Formulary
|
Tablets 100mg On advice of Microbiology only. Posaconazole tablets and oral suspension are not bioequivalent and should not be used interchangeably, due to differences in dosing frequency, administration with regards to food, and the plasma-drug concentration achieved. |
|
MHRA: Posaconazole (Noxafil): tablets and oral suspension are not directly interchangeable |
|
|
| Voriconazole |
|
Formulary
|
Tablets 50mg, 200mg On advice of Microbiology only. |
|
MHRA: Voriconazole: reminder of risk of liver toxicity, phototoxicity, and squamous cell carcinoma |
|
|
Links
- BASHH: Vulvovaginal Candidiasis 2019
Blackpool Teaching Hospitals: Antimicrobial Formulary- British Association for Sexual Health and HIV
- Dapsone for the treatment of Dermatitis Herpetiformis, other dermatoses and Vasculitis shared care guideline
- East Lancashire Primary Care: Antimicrobial guide primary care
- East Lancashire Secondary Care: Antimicrobial guide secondary care
- Greater Preston, Chorley and South Ribble/LSCFT/Morecambe Bay Primary Care: NICE Summary of antimicrobial prescribing guidance - managing common infections
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (App store)
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (Google)
- LSCMMG Recurrent UTI Prophylactic Antibiotic Pathway
- MHRA Drug Safety Update July 2018: Parenteral amphotericin B: reminder of risk of potentially fatal adverse reaction if formulations confused
- MHRA Drug Safety Update July 2020: Liposomal and lipid-complex formulations: name change to reduce medication errors
- MHRA Drug Safety Update Oct 2020: Flucytosine (Ancotil): new contraindication in patients with DPD deficiency
- MHRA Drug Safety Update Sept 2016: Posaconazole (Noxafil): tablets and oral suspension are not directly interchangeable
- MHRA Drug Safety Update:Voriconazole Dec 2014: reminder of risk of liver toxicity, phototoxicity, and squamous cell carcinoma
- MHRA: Flucytosine (Ancotil): new contraindication in patients with DPD deficiency
- MHRA: Liposomal and lipid-complex formulations: name change to reduce medication errors
- MHRA: Miconazole (Daktarin): over-the-counter oral gel contraindicated in patients taking warfarin
- MHRA: Parenteral amphotericin B: reminder of risk of potentially fatal adverse reaction if formulations confused
- MHRA: Posaconazole (Noxafil): tablets and oral suspension are not directly interchangeable
- MHRA: Topical miconazole, including oral gel: reminder of potential for serious interactions with warfarin
- MHRA: Voriconazole: reminder of risk of liver toxicity, phototoxicity, and squamous cell carcinoma
- NICE CG165: Hepatitis B (chronic): diagnosis and management
- NICE CG97: Lower urinary tract symptoms in men: management
- NICE NG109: Urinary tract infection (lower): antimicrobial prescribing
- NICE NG112: Urinary tract infection (recurrent): antimicrobial prescribing
- NICE NG113: Urinary tract infection (catheter-associated): antimicrobial prescribing
- NICE NG120: Cough (acute): antimicrobial prescribing
- NICE NG125: Surgical site infections: prevention and treatment
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG240: Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management
- NICE NG51: Sepsis: recognition, diagnosis and early management
- NICE NG78: Cystic fibrosis: diagnosis and management
- NPSA alert on injectable amphotericin
- NPSA Rapid response report - Non-lipid and lipid formulations of injectable amphotericin
- University Hospitals of Morecambe Bay: Antimicrobial guide secondary care
- West Lancashire Primary Care: Pan Mersey antimicrobial guide
- WHO: AWaRe classification of antibiotics for evaluation and monitoring of use, 2023